pSivida Announces Pricing of $16 Million Public Offering of Common Stock
The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT:LTS) and
The offering is expected to close on or about
The securities described above are being offered by pSivida pursuant to a registration statement on Form S-3 previously filed and declared effective by the
This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in the offering, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About pSivida Corp. pSivida Corp., headquartered in Watertown, MA, is a leader in the development of sustained release, drug delivery products for treating eye diseases. pSivida has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases. The most recent, ILUVIEN®, a micro-insert for diabetic macular edema, licensed to Alimera Sciences, is currently sold in the
Certain statements contained in this release, including those relating to the expected closing of the offering, are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These
risks and uncertainties include, but are not limited to: pSivida's ability to successfully complete the offering; the volatility of the company's stock price may prevent shares purchased in the offering from being resold at or above the price paid for them; purchasers of shares in the offering will suffer immediate and substantial dilution; and other risk factors identified from time to time in the reports pSivida files with the
Beverly JedynakO: 312-943-1123 M: 773-350-5793 firstname.lastname@example.org
News Provided by Acquire Media